Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 6/20 | 1.00 |
| ▸ | DRD3 | P35462 | 5/20 | 1.00 |
| ▸ | TH | P07101 | 4/20 | 1.00 |
| ▸ | MAPT | P10636 | 4/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 4/20 | 1.00 |
| ▸ | DRD1 | P21728 | 4/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 1.00 |
| ▸ | LMNA | P02545 | 3/20 | 1.00 |
| ▸ | HPGD | P15428 | 3/20 | 1.00 |
| ▸ | PMP22 | Q01453 | 3/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 3/20 | 1.00 |
| ▸ | GMNN | O75496 | 2/20 | 1.00 |
| ▸ | GFER | P55789 | 2/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 1.00 |
| ▸ | RGS12 | O14924 | 2/20 | 1.00 |
| ▸ | TP53 | P04637 | 2/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 2/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 2/20 | 1.00 |
| ▸ | THPO | P40225 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| R-N-Propylnorapomorphine SCHEMBL29447877 | 1.00 | DRD2 (1.00) | DRD2DRD3THMAPTMAPK1 | |
| R-N-Propylnorapomorphine SCHEMBL13487203 | 1.00 | DRD2 (1.00) | DRD2DRD3THMAPTMAPK1 | |
| R-N-Propylnorapomorphine SCHEMBL13398114 | 1.00 | DRD2 (1.00) | DRD2DRD3THMAPTMAPK1 | |
| R-N-Propylnorapomorphine SCHEMBL7997518 | 1.00 | DRD2 (1.00) | DRD2DRD3THMAPTMAPK1 | |
| SCHEMBL14161595 | 0.91 | MAPT (0.83) | DRD2DRD3THMAPTMAPK1 | |
| SCHEMBL1203698 | 0.90 | DRD2 (1.00) | DRD2DRD3THMAPTMAPK1 | |
| SCHEMBL10754712 | 0.90 | DRD2 (1.00) | DRD2DRD3THMAPTMAPK1 | |
| SCHEMBL1203699 | 0.90 | DRD2 (1.00) | DRD2DRD3THMAPTMAPK1 | |
| SCHEMBL19815875 | 0.89 | DRD2 (1.00) | DRD2DRD3THMAPTMAPK1 | |
| Hydrochloric Acid SCHEMBL10752801 | 0.88 | DRD2 (0.98) | DRD2DRD3THMAPTMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 320 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4717276-A2 | OPHTHALMIC COMPOSITIONS COMPRISING LEVODOPA, AN ANTIOXIDANT AND AN AQUEOUS CARRIER | University of Canberra (AU) | 2026-04-01 | — | — | EP | claimed |
| EP-3442516-B1 | OPHTHALMIC COMPOSITIONS COMPRISING LEVODOPA, AN ANTIOXIDANT AND AN AQUEOUS CARRIER | UNIV CANBERRA (AU) | 2025-11-12 | — | — | EP | claimed |
| WO-2025151884-A1 | USE OF GLYCOSAMINOGLYCAN SULFATED POLYSACCHARIDES SUCH AS SODIUM PENTOSAN POLYSULFATE IN COMBINATION WITH PERMEATION AGENTS TO TREAT ALZHEIMER'S DISEASE | PARSONS C LOWELL (US) | 2025-07-17 | — | — | WO | claimed |
| CN-112770734-B | Inhibition method | 堪培拉大学 | 2024-08-20 | — | — | CN | claimed |
| EP-4335504-A2 | TREATMENT OF MOVEMENT DISORDERS | Contera Pharma ApS (DK) | 2024-03-13 | — | — | EP | claimed |
| US-11890266-B2 | Ophthalmic compositions including levodopa, an antioxidant and an aqueous carrier | UNIVERSITY OF CANBERRA (AU) | 2024-02-06 | — | — | US | claimed |
| EP-3897641-B1 | TREATMENT OF MOVEMENT DISORDERS | CONTERA PHARMA AS (DK) | 2023-11-15 | — | — | EP | claimed |
| EP-3448379-B1 | TREATMENT OF IMPULSIVITY-RELATED DISORDERS | UNIV OXFORD INNOVATION LTD (GB) | 2023-06-28 | — | — | EP | claimed |
| EP-4178948-A2 | FUNCTIONALIZED ISONITRILES AND PRODUCTS, PREPARATION AND USES THEREOF | Universidade de Santiago de Compostela (ES) | 2023-05-17 | — | — | EP | claimed |
| EP-4003348-A1 | COMPOUNDS AND METHODS FOR TREATING FIBROTIC PATHOLOGIES | Mayo Foundation for Medical Education and Research (US) | 2022-06-01 | — | — | EP | claimed |
| US-20100172916-A1 | SUBSTITUTED HYDROXYPHENYLAMINE COMPOUNDS | AUSPEX PHARMACEUTICALS, INC. (US) | 2010-07-08 | — | — | US | claimed |
| WO-2010060070-A2 | INDOLINONE MODULATORS OF DOPAMINE RECEPTOR | AUSPEX PHARMACEUTICALS, INC. (US) | 2010-05-27 | — | — | WO | claimed |
| US-20100130582-A1 | INDOLINONE MODULATORS OF DOPAMINE RECEPTOR | AUSPEX PHARMACEUTICALS, INC. (US) | 2010-05-27 | — | — | US | claimed |
| WO-2010054286-A2 | SUBSTITUTED HYDROXYPHENYLAMINE COMPOUNDS | AUSPEX PHARMACEUTICALS, INC. (US) | 2010-05-14 | — | — | WO | claimed |
| WO-2009078034-A2 | ORAL DISINTEGRATING TABLETS OF ROPINIROLE HYDROCHLORIDE | RUBICON RESEARCH PRIVATE LIMITED (IN) | 2009-06-25 | — | — | WO | claimed |
| US-20090076019-A1 | METHODS FOR TREATING NEUROLOGICAL DISORDERS OR DAMAGE | MOUNT SINAI HOSPITAL (CA) | 2009-03-19 | — | — | US | claimed |
| US-20070117788-A1 | Combination of a dopamine D2-receptor agonist and tiotropium or a derivative therof for treating obstructive airways and other inflammatory diseases | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2007-05-24 | — | — | US | claimed |
| EP-1397134-A2 | COMBINATION OF A DOPAMINE D2-RECEPTOR AGONIST AND TIOTROPIUM OR A DERIVATIVE THEROF FOR TREATING OBSTRUCTIVE AIRWAYS | Boehringer Ingelheim Pharma GmbH & Co.KG (DE) | 2004-03-17 | — | — | EP | claimed |
| WO-2002096422-A2 | COMBINATION OF A DOPAMINE D2-RECEPTOR AGONIST AND TIOTROPIUM OR A DERIVATIVE THEREOF FOR TREATING OBSTRUCTIVE AIRWAYS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2002-12-05 | — | — | WO | claimed |
| WO-1996004910-A1 | TREATMENT OF OPIATE WITHDRAWAL SYNDROME | HAHNEMANN UNIVERSITY (US) | 1996-02-22 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070117788-A1 | Combination of a dopamine D2-receptor agonist and tiotropium or a derivative therof for treating obstructive airways and other inflammatory diseases | CHRM2, ADRB2, CHRM3 | DRD2 33/4885DRD3 39/4885TH 64/4885 |
| US-20100130582-A1 | INDOLINONE MODULATORS OF DOPAMINE RECEPTOR | HTR2A, HTR3B, MTNR1A | DRD2 63/4885DRD3 108/4885TH 411/4885 |
| US-20100172916-A1 | SUBSTITUTED HYDROXYPHENYLAMINE COMPOUNDS | MC1R, TYR, MITF | DRD2 855/4885DRD3 717/4885TH 47/4885 |
| US-11890266-B2 | Ophthalmic compositions including levodopa, an antioxidant and an aqueous carrier | TTPA, TST, TXN2 | DRD2 2171/4885DRD3 1985/4885TH 116/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.